PHARMACOGENETICS OF PAROXETINE FOR AUTISM

帕罗西汀治疗自闭症的药物遗传学

• 批准号: 7378606
• 负责人: THOMAS B OWLEY
• 金额: $ 0.14万
• 依托单位: UNIVERSITY OF CHICAGO
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-05-18 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378606
• 关键词: autism; children; genes; paroxetine; serotonin; serotonin inhibitor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a study of the treatment of children with autism spectrum disorders with the medication escitalopram. This medication is a serotonin reuptake inhibitor. These medications have been found to be helpful in this group of children. However, the dosing is very difficult to predict. Therefore, we are looking at particular genes in the serotonin system to see if these genes predict for dosing differences, as well as differences in tolerability and efficacy.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。这是一项关于艾司西酞普兰治疗自闭症谱系障碍儿童的研究。这种药是血清素再摄取抑制剂。这些药物被发现对这类儿童有帮助。然而，剂量很难预测。因此，我们正在研究5-羟色胺系统中的特定基因，看看这些基因是否预测剂量差异，以及耐受性和疗效的差异。